Comparative assessment of a metabolically attenuated Mycoplasma gallisepticum mutant as a live vaccine for the prevention of avian respiratory mycoplasmosis

A. E. Gates, S. Frasca, Carol A Nyaoke, T. S. Gorton, L. K. Silbart, S. J. Geary

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

In a previous study, signature sequence mutagenesis (SSM) was used to identify a mutant with a disruption of the gene encoding the metabolic factor, dihydrolipoamide dehydrogenase, and that mutant was designated Mg 7. The current study assessed the safety, immunogenicity and efficacy of Mg 7 in comparison to two commercially available vaccines (ts-11 and F) as well as a laboratory vaccine strain, GT5. Intratracheal vaccination of chickens with all four attenuated mutants induced varying levels of protection against intratracheal challenge with virulent Mycoplasma gallisepticum strain Rlow. Mg 7 vaccinated chickens rapidly cleared the challenge strain, had lower histopathologic tracheal lesion scores when compared to unvaccinated chickens, and mounted a strong humoral anti-M. gallisepticum-specific IgG response. The IgG levels increased 2- to 3-fold upon Rlow challenge. Mg 7 induced a greater level of protection against intratracheal Rlow challenge than that observed with the other three attenuated strains, as evidenced by a lower recovery of Rlow from tracheas and lower histopathologic lesion scores in tracheas and air sacs. Based on these findings, Mg 7 appears to have good potential as a safe and effective vaccine for the prevention of avian mycoplasmosis.

Original languageEnglish (US)
Pages (from-to)2010-2019
Number of pages10
JournalVaccine
Volume26
Issue number16
DOIs
StatePublished - Apr 7 2008
Externally publishedYes

Fingerprint

Mycoplasma gallisepticum
mycoplasmosis
live vaccines
Chickens
Vaccines
Trachea
trachea (vertebrates)
mutants
vaccines
chickens
Immunoglobulin G
lesions (animal)
Dihydrolipoamide Dehydrogenase
Air Sacs
Mutagenesis
air sacs
Vaccination
gene targeting
mutagenesis
Safety

Keywords

  • Mycoplasma gallisepticum
  • Respiratory disease
  • Vaccine

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Comparative assessment of a metabolically attenuated Mycoplasma gallisepticum mutant as a live vaccine for the prevention of avian respiratory mycoplasmosis. / Gates, A. E.; Frasca, S.; Nyaoke, Carol A; Gorton, T. S.; Silbart, L. K.; Geary, S. J.

In: Vaccine, Vol. 26, No. 16, 07.04.2008, p. 2010-2019.

Research output: Contribution to journalArticle

Gates, A. E. ; Frasca, S. ; Nyaoke, Carol A ; Gorton, T. S. ; Silbart, L. K. ; Geary, S. J. / Comparative assessment of a metabolically attenuated Mycoplasma gallisepticum mutant as a live vaccine for the prevention of avian respiratory mycoplasmosis. In: Vaccine. 2008 ; Vol. 26, No. 16. pp. 2010-2019.
@article{940a46b3a85f42c798117fe748a2f2c7,
title = "Comparative assessment of a metabolically attenuated Mycoplasma gallisepticum mutant as a live vaccine for the prevention of avian respiratory mycoplasmosis",
abstract = "In a previous study, signature sequence mutagenesis (SSM) was used to identify a mutant with a disruption of the gene encoding the metabolic factor, dihydrolipoamide dehydrogenase, and that mutant was designated Mg 7. The current study assessed the safety, immunogenicity and efficacy of Mg 7 in comparison to two commercially available vaccines (ts-11 and F) as well as a laboratory vaccine strain, GT5. Intratracheal vaccination of chickens with all four attenuated mutants induced varying levels of protection against intratracheal challenge with virulent Mycoplasma gallisepticum strain Rlow. Mg 7 vaccinated chickens rapidly cleared the challenge strain, had lower histopathologic tracheal lesion scores when compared to unvaccinated chickens, and mounted a strong humoral anti-M. gallisepticum-specific IgG response. The IgG levels increased 2- to 3-fold upon Rlow challenge. Mg 7 induced a greater level of protection against intratracheal Rlow challenge than that observed with the other three attenuated strains, as evidenced by a lower recovery of Rlow from tracheas and lower histopathologic lesion scores in tracheas and air sacs. Based on these findings, Mg 7 appears to have good potential as a safe and effective vaccine for the prevention of avian mycoplasmosis.",
keywords = "Mycoplasma gallisepticum, Respiratory disease, Vaccine",
author = "Gates, {A. E.} and S. Frasca and Nyaoke, {Carol A} and Gorton, {T. S.} and Silbart, {L. K.} and Geary, {S. J.}",
year = "2008",
month = "4",
day = "7",
doi = "10.1016/j.vaccine.2008.02.010",
language = "English (US)",
volume = "26",
pages = "2010--2019",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "16",

}

TY - JOUR

T1 - Comparative assessment of a metabolically attenuated Mycoplasma gallisepticum mutant as a live vaccine for the prevention of avian respiratory mycoplasmosis

AU - Gates, A. E.

AU - Frasca, S.

AU - Nyaoke, Carol A

AU - Gorton, T. S.

AU - Silbart, L. K.

AU - Geary, S. J.

PY - 2008/4/7

Y1 - 2008/4/7

N2 - In a previous study, signature sequence mutagenesis (SSM) was used to identify a mutant with a disruption of the gene encoding the metabolic factor, dihydrolipoamide dehydrogenase, and that mutant was designated Mg 7. The current study assessed the safety, immunogenicity and efficacy of Mg 7 in comparison to two commercially available vaccines (ts-11 and F) as well as a laboratory vaccine strain, GT5. Intratracheal vaccination of chickens with all four attenuated mutants induced varying levels of protection against intratracheal challenge with virulent Mycoplasma gallisepticum strain Rlow. Mg 7 vaccinated chickens rapidly cleared the challenge strain, had lower histopathologic tracheal lesion scores when compared to unvaccinated chickens, and mounted a strong humoral anti-M. gallisepticum-specific IgG response. The IgG levels increased 2- to 3-fold upon Rlow challenge. Mg 7 induced a greater level of protection against intratracheal Rlow challenge than that observed with the other three attenuated strains, as evidenced by a lower recovery of Rlow from tracheas and lower histopathologic lesion scores in tracheas and air sacs. Based on these findings, Mg 7 appears to have good potential as a safe and effective vaccine for the prevention of avian mycoplasmosis.

AB - In a previous study, signature sequence mutagenesis (SSM) was used to identify a mutant with a disruption of the gene encoding the metabolic factor, dihydrolipoamide dehydrogenase, and that mutant was designated Mg 7. The current study assessed the safety, immunogenicity and efficacy of Mg 7 in comparison to two commercially available vaccines (ts-11 and F) as well as a laboratory vaccine strain, GT5. Intratracheal vaccination of chickens with all four attenuated mutants induced varying levels of protection against intratracheal challenge with virulent Mycoplasma gallisepticum strain Rlow. Mg 7 vaccinated chickens rapidly cleared the challenge strain, had lower histopathologic tracheal lesion scores when compared to unvaccinated chickens, and mounted a strong humoral anti-M. gallisepticum-specific IgG response. The IgG levels increased 2- to 3-fold upon Rlow challenge. Mg 7 induced a greater level of protection against intratracheal Rlow challenge than that observed with the other three attenuated strains, as evidenced by a lower recovery of Rlow from tracheas and lower histopathologic lesion scores in tracheas and air sacs. Based on these findings, Mg 7 appears to have good potential as a safe and effective vaccine for the prevention of avian mycoplasmosis.

KW - Mycoplasma gallisepticum

KW - Respiratory disease

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=40849123833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40849123833&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2008.02.010

DO - 10.1016/j.vaccine.2008.02.010

M3 - Article

C2 - 18342996

AN - SCOPUS:40849123833

VL - 26

SP - 2010

EP - 2019

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 16

ER -